Important note: Information in this article was accurate in 2003. The state of the art may have changed since the publication date.
PRNewswire - November 11, 2003
Twenty-two (22) patients receiving stable, failing highly active antiretroviral therapy (HAART) or no background therapy were given received weekly or bi-weekly intravenous infusions of TNX-355 for 8 or 9 weeks.
TNX-355 therapy was well tolerated and associated with initial, clinically meaningful reductions in viral load. Recovery in viral load was associated with decreased in vitro sensitivity to TNX-355. Detailed results from this trial will be presented within the next several months, and a Phase 2 study of TNX-355 in combination with optimized background therapy in patients failing HAART is being planned for 2004.
TNX-355, recently granted fast track status by the U.S. Food and Drug Administration (FDA), is a humanized, non-immunosuppressive anti-CD4 monoclonal antibody being developed by Tanox for the treatment of HIV-1 infection. TNX-355 is designed to block cellular infection by binding to the CD4 receptor on host cell surfaces that is considered to be a gateway for HIV infection. TNX-355 appears to prevent post-viral binding conformational changes in gp120, gp41, and/or CD4 needed for the virus to enter the cell. This monoclonal antibody is one of a new class of drugs called viral entry inhibitors.
About Tanox
Tanox, Inc. is a biopharmaceutical company with demonstrated expertise in monoclonal antibody technology. The Company is engaged in the discovery and development of therapeutic monoclonal antibodies designed to address significant unmet medical needs in the areas of asthma, allergy, inflammation and other diseases affecting the human immune system. In June 2003, the U.S. Food and Drug Administration approved Xolair(R) For Subcutaneous Use for treatment of adults and adolescents (12 years of age and above) with moderate- to-severe persistent asthma who have a positive skin test or in vitro reactivity to a perennial aeroallergen and whose symptoms are inadequately controlled with inhaled corticosteroids. Xolair(R), Tanox's first approved drug, is an anti-immunoglobulin E, or anti-IgE, antibody that was developed under a collaboration agreement among Genentech, Inc., Novartis Pharma AG and Tanox, Inc.
This release and other information about Tanox, Inc. can be found on the World Wide Web at http://www.tanox.com .
This news release contains forward-looking statements that involve significant risks and uncertainties, including those discussed below and more fully described in the Securities and Exchange Commission reports filed by Tanox, including our most recent Form 10-Q. Tanox conducts research in the biotechnology/ pharmaceutical field where movement from concept to product is uncertain; consequently, there can be no guarantee that any particular product candidate will be successful and become a commercial product. In addition, while we routinely obtain patents for our products and technology, the protection offered by our patents and patent applications may be challenged, invalidated or circumvented by our competitors. Because forward-looking statements involve risks and uncertainties, actual results may differ materially from current results expected by Tanox.
SOURCE Tanox, Inc.
Web Site: http://www.tanox.com
031111
PR031114
Copyright © 2003 - PRNewswire. All rights reserved. Reproduced with permission. Reproduction of this article (other than one copy for personal reference) must be cleared through PRNewswire, Permissions, 810 Seventh Ave., 32nd Floor, New York, NY 10019 http://www.prnewswire.com.
AEGiS is a 501(c)3, not-for-profit, tax-exempt, educational corporation. AEGiS is made possible through unrestricted funding from Broadway Cares/Equity Fights AIDS, Elton John AIDS Foundation, the National Library of Medicine, Pacific Life Foundation and donations from users like you.
Always watch for outdated information. This article first appeared in 2003. This material is designed to support, not replace, the relationship that exists between you and your doctor.
AEGiS presents published material, reprinted with permission and neither endorses nor opposes any material. All information contained on this website, including information relating to health conditions, products, and treatments, is for informational purposes only. It is often presented in summary or aggregate form. It is not meant to be a substitute for the advice provided by your own physician or other medical professionals. Always discuss treatment options with a doctor who specializes in treating HIV.
Copyright ©1980, 2003. AEGiS. All materials appearing on AEGiS are protected by copyright as a collective work or compilation under U.S. copyright and other laws and are the property of AEGiS, or the party credited as the provider of the content. .